Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + nivolumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bevacizumab + nivolumab is a combination of two monoclonal antibody drugs used in oncology. Bevacizumab is an anti-angiogenic agent that targets and neutralizes vascular endothelial growth factor A (VEGF-A), thereby inhibiting tumor angiogenesis and reducing blood supply to tumors. Nivolumab is an immune checkpoint inhibitor that targets the programmed cell death protein 1 (PD-1) receptor on T cells, blocking its interaction with PD-L1/PD-L2 and enhancing the immune system's ability to recognize and destroy cancer cells. This combination has been investigated for synergistic effects in various cancers, including relapsed ovarian cancer and advanced nonsquamous non-small-cell lung cancer (NSCLC). Clinical studies have shown activity in platinum-sensitive ovarian cancer as well as improved progression-free survival when combined with chemotherapy for NSCLC[1][3][5].
- Other names
- nivolumab + bevacizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on bevacizumab + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + nivolumab.